Waters Corporation (WAT) has a MoatMap StockRank of 50/100 based on Quality (58/100), Value (20/100), and Momentum (59/100) factor scores. The current signal is HOLD. Waters Corporation is a high-quality provider of analytical instruments (liquid chromatography and mass spectrometry) essential for drug development and manufacturing validation. While it stands to benefit from the CDMO pricing power cycle as biologics manufacturing scales, near-term biopharma spending caution and high valuation warrant a cautious, monitored stance.
Waters Corporation develops and manufactures analytical laboratory instruments, software, and services for liquid chromatography, mass spectrometry, and thermal analysis, serving pharmaceutical, life science, and industrial research. It is a market leader in high-performance liquid chromatography (HPLC) and mass spectrometry, benefiting from a deeply embedded installed base, proprietary technologies, and high customer switching costs. Waters is a critical enabler of scientific research and quality control across diverse industries.
| Price | $365.55 |
| Market Cap | $36.0B |
| P/E (TTM) | 47.84 |
| P/E (Forward) | 22.86 |
| Price/Book | 8.75 |
| Return on Equity | 5.2% |
| Return on Invested Capital | 21.5% |
| Debt/Equity | 36.63 |
| Gross Margin | 55.2% |
| Operating Margin | 2.8% |
| Revenue Growth | 91.4% |
| Free Cash Flow | $-502M |
Waters Corporation operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).